Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415176 | 0.85 | ADORA2A (0.54) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4668103 | 0.85 | ADORA2A (0.54) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5225967 | 0.85 | ADORA2A (0.54) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL1415177 | 0.85 | ADORA2A (0.54) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL589466 | 0.85 | ADORA2A (0.54) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL589387 | 0.81 | ADORA3 (0.58) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL589029 | 0.80 | LMNA (0.39) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL1412441 | 0.80 | LMNA (0.39) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL590069 | 0.80 | ADORA3 (0.51) | ADORA3ADORA1ADORA2AADORA2BCDK1 | |
| SCHEMBL2812121 | 0.79 | ADORA3 (0.53) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| EP-2018388-B9 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-2018388-B1 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2011-03-16 | — | — | EP | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| EP-2012759-B1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| EP-2018388-A2 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| WO-2007121924-A2 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA1 3/4885ADORA2A 1/4885 |
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | ADORA3 1044/4885ADORA1 697/4885ADORA2A 1137/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA1 2/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.